ClinicalTrials.gov
ClinicalTrials.gov Menu

Development of Predictive Biomarkers and Novel Approached to Therapy in Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01051492
Recruitment Status : Unknown
Verified January 2014 by National University Hospital, Singapore.
Recruitment status was:  Recruiting
First Posted : January 18, 2010
Last Update Posted : January 14, 2014
Sponsor:
Information provided by:
National University Hospital, Singapore

Brief Summary:
Breast cancer is a common malignancy world-wide, and is the commonest female malignancy in Singapore, with rising trends in incidence over the last 2 decades. While there have been improvements in treatment, mortality from breast cancer remains significant. Development of biomarkers to predict treatment response and toxicity to anti-cancer agents can rationalize the choice of therapy for the individual patients to optimize treatment outcome and to reduce unnecessary toxicities. Development of novel therapies or novel approaches to therapy is also critical to improve the treatment armamentarium in breast cancer. These research strategies will have an significant impact on breast cancer treatment both in Singapore as well as globally.

Condition or disease
Breast Cancer

Study Type : Observational
Observational Model: Case-Crossover
Time Perspective: Cross-Sectional
Study Start Date : January 2010
Estimated Primary Completion Date : December 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
U.S. FDA Resources





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Any individual who has been diagnosed with breast cancer
Criteria

Inclusion Criteria:

This program will recruit mainly cancer patients, predominantly breast cancer patients. The exact inclusion criteria will vary between each individual study. Each individual component study will be submitted to DSRB for separate approval, along with the study protocol and patient informed consent sheet.

Exclusion Criteria:

The exact exclusion criteria will vary between each individual study. Each individual component study will be submitted to DSRB for separate approval, along with the study protocol and patient informed consent sheet.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01051492


Contacts
Contact: Soo Chin Lee, MBBS, MRCP 65 6772 4629 soo_chin_lee@nuhs.edu.sg

Locations
Singapore
National University Hospital Singapore Recruiting
Singapore, Singapore
Contact: Soo Chin Lee, MBBS, MRCP    65 6772 4629    soo_chin_lee@nuhs.edu.sg   
Principal Investigator: Soo Chin Lee, MBBS, MRCP         
Sponsors and Collaborators
National University Hospital, Singapore